SUBSCRIBE
SUBSCRIBE
News   Drug Development

Neurosearch A/S Announces New Findings From the MermaiHD Phase III Study Supporting Potential Disease Modifying Properties of Huntexil(R)

March 8, 2010 | 
1 min read
COPENHAGEN and BALLERUP, Denmark, March 8, 2010 (GLOBE NEWSWIRE) -- NeuroSearch (NEUR) today announced that further analysis of the data from the MermaiHD study with Huntexil(R) (pridopidine) for the treatment of Huntington's disease supports potential disease modifying properties of the drug.
Clinical research Phase III Europe
MORE ON THIS TOPIC
Podcast
M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s
October 1, 2025
 · 
2 min read
 · 
Heather McKenzie
Tablets. Medicinal capsules on a white background. pharmacies in the country. medicines in the state. Lots of capsules for treatment. Pharmacy network of the country.
Opinion
The Urgent Need To Redefine the Future of UK Biotech
October 1, 2025
 · 
6 min read
 · 
Kerstin Papenfuss
Achieve goal concept art collage. Rising arrow chart and halftone hand pointing to center of dartboard. Business goal, achieve targets, success. Trendy modern retro vector illustration
Obesity
Metsera’s Obesity Drug Shows ‘Very Encouraging’ Mid-Stage Efficacy, Supporting Pfizer’s $4.9B Bet
September 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Friedreich’s ataxia
Larimar’s Friedreich’s Ataxia Drug Troubled by Anaphylaxis Concerns; Shares Fall
September 30, 2025
 · 
2 min read
 · 
Tristan Manalac